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Abstract 
Introduction: Antineoplastic chemotherapy remains one of the most widely used management strategies in cancer, 
either alone or in combination with other types of treatment. The main inconvenience of chemotherapy is its lack 
of selectivity, since it acts upon both tumor cells and rapidly multiplying normal cells such as bone marrow cells, 
hair follicle cells and oral and gastrointestinal mucosal cells.
Material and method: An exhaustive search was made of the main oral toxic effects of chemotherapy in the Pub-
Med-Medline, Cochrane Library and Scopus databases. A total of 1293 articles were identified, of which 333 met 
the study inclusion criteria.
Results: The toxic effects of chemotherapy at oral mucosal level comprise mucositis, osteonecrosis of the jaws se-
condary to bisphosphonate use, susceptibility to infections, dental alterations, salivary and neurological disorders, 
dysgeusia and bleeding tendency. These complications have a negative impact upon patient quality of life, and in 
some cases can prove life-threatening.
Conclusions: Evaluation of patient oral and dental health is essential before administering chemotherapy, in order 
to minimize the risk of oral and systemic complications of such treatment.
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Introduction
In global terms, cancer is characterized by increased cell 
proliferation and diminished apoptosis (1). The prolife-
ration of atypical cells gives rise to invasive capacity, 
with the infiltration of body tissues or organs through 
the bloodstream or lymphatic system – this process be-
ing known as metastasis. The existing cancer treatments 
comprise surgery and radiotherapy, chemotherapy, bio-
logical or immune therapy, hormonal therapy and gene 
therapy (a form of treatment that is still in the inves-
tigational stage) (2), which aim to block cell prolifera-
tion (1). Despite the advances in cancer management, 
chemotherapy remains one of the most widely used 
treatment modalities, either alone or in combination with 
other types of treatment (3,4). The great inconvenience 
of chemotherapy is its lack of selectivity, since it acts 
upon both tumor cells and rapidly multiplying normal 
cells (1,3-5).
The oral cavity is very susceptible to the direct and indi-
rect toxic effects of chemotherapy. This is due to a num-
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Oral toxicity produced by the administration of 
chemotherapy 
The oral complications of chemotherapy are either a re-
sult of direct action of the drug upon the oral mucosa 
(direct stomatological toxicity), or an indirect conse-
quence of chemotherapeutic drug-induced bone marrow 
suppression or myelosuppression (indirect stomatologi-
cal toxicity)(3,4). 
1.Mucosal toxicity
The cells of the oral cavity have a fast turnover rate, with 
a cycle of 7-14 days. This explains the special suscepti-
bility of the oral mucosa to the toxic effects of cytostatic 
drugs (3).
- Terminology
There is some debate regarding the terminology used in 
reference to the mucosal alterations produced by can-
cer treatment. Some authors prefer the term “stomati-
tis”, since the term “mucositis” can refer to any mucosal 
membrane of the gastrointestinal tract (6). However, 
there appears to be agreement in the international lite-
rature on the use of the term “oral mucositis” or “buc-
cal mucositis”. This term, introduced in the late 1980s, 
refers to inflammation of the oral mucosa induced by 
radiotherapy (seen in 80% of all patients), chemotherapy 
(in approximately 40-50%), or bone marrow transplan-
tation (in over 75% of all patients), and is considered a 
manifestation of leukopenia (4,6).
- Physiopathology
The pathogenesis of oral mucositis has not been fully 
clarified. According to the hypothesis of Sonis et al., 
mucositis comprises four phases. The first phase (infla-
ber of factors, including the high cellular turnover rate 
of the oral mucosa, the complex and diverse microflora 
of the oral cavity, and oral tissue trauma occurring du-
ring normal oral function (3,4). It is therefore essential 
to evaluate the oral condition of the patient and to stabi-
lize any oral disease conditions before cancer treatment 
is provided (5). Oncological patient care must be viewed 
from both the preventive and therapeutic perspectives, 
in order to minimize the risk of oral complications and 
other related systemic complications (4).
The present systematic review offers an update on the 
main oral toxic effects of chemotherapy, based on the 
data found in the scientific literature. 
Material and Methods
An exhaustive search was made of the PubMed-Medli-
ne, Cochrane Library and Scopus databases, using the 
following keywords: “oral complications”, “oral muco-
sitis”, “oral candidiasis”, “periodontal disease”, “gin-
givitis”, “caries”, “oral infection”, “dental develop-
ment”, “dysgeusia”, “taste disturbances”, “saliva” and 
“osteonecrosis jaw”, related by means of the boolean 
operators “AND” and “NOT” to the terms “chemothe-
rapy” and “radiotherapy”, respectively. We included 
human studies as well as reviews published in English 
or Spanish during the last 10 years (from January 2002 
to December 2012). Opinion articles, series with fewer 
than 5 cases, and studies involving radiotherapy and/or 
the bone marrow transplantation as sole or concomitant 
treatments were excluded. A total of 1293 articles were 
identified, of which 333 met the study inclusion criteria 
(Table 1).
PUBMED COCHRANE SCOPUS TOTAL TYPE OF STUDY
DISORDER N n N n N n N n* Tri-al
Co-
hort
Case-
control
Cross-
sectional
Case 
series
Revi-
sion 
ORAL COMPLICATIONS 23 12 4 1 89 28 116 47 15 6 4 5 4 13
ORAL MUCOSITIS 202 127 36 25 93 25 331 116 51 12 4 7 2 40
DENTAL DEVELOPMENT 15 5 0 0 48 6 63 6 0 0 5 1 0 0
DYSGEUSIA 19 6 3 3 22 8 44 12 3 4 0 0 1 4
TASTE ALTERATIONS 3 3 3 3 1 0 7 5 1 1 0 1 0 2
SALIVA 40 9 8 1 26 4 74 13 1 2 4 1 1 4
CANDIDIASIS 26 12 35 4 18 8 79 28 7 4 1 2 1 13
PERIODONTAL 
DISEASE, GINGIVITIS, 
CARIES, VIRAL 
INFECTIONS
162 30 22 0 30 4 214 27 1 11 2 5 4 4
BRONJ 72 53 18 2 275 60 365 79 9 7 3 2 14 44
TOTAL 562 257 129 39 602 143 1293 333 88 47 23 24 27 124
Table 1. Types of reviewed studies on the oral complications of chemotherapy published in the literature (2002-2012). // N: studies identified 
from the search; n: selected studies; n*: selected studies eliminating articles appearing in more than one database; BRONJ: bisphosphonate-related 
osteonecrosis of the jaw.
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mmatory/vascular phase) occurs after the administration 
of chemotherapy, with the release of cytokines from the 
epithelium (tumor necrosis factor-alpha, interleukins 1 
and 6), producing local tissue damage that leads to early 
stage mucositis. In phase 2, and as a result of the cancer 
treatment, epithelial renewal or turnover decreases, with 
mucosal atrophy and ulceration. These first two phases 
manifest about 0-5 days after treatment administration. 
Phase 3 develops one week after the start of antineo-
plastic therapy, and is characterized by epithelial rupture 
and the appearance of a fibrinous exudate that favors the 
development of pseudomembranes and ulcers. This is 
generally the most symptomatic phase, since it coincides 
with the period of maximum neutropenia or secondary 
bacterial colonization (1). The fourth phase involves 
healing (cicatrization) and generally occurs after 12-16 
days. It is dependent upon the proliferative capacity of 
the epithelium, hematopoietic recovery, restoration of 
the oral microflora, and the absence of factors such as 
infection and mechanical irritation (7).
- Risk factors
A number of risk factors influencing the frequency and 
severity of mucositis have been described. Some are 
inherent to the patient, such as the type of tumor (he-
matological disease)(6,8), age (young patients)(6), oral 
and dental health (poor oral hygiene before and during 
chemotherapy)(9), the nutritional condition of the pa-
tient, and the maintenance of liver and kidney function. 
In turn, other risk factors are related to the administe-
red drug, such as the type of cytostatic agent used (Ta-
ble 2)(10), the frequency of administration (prolonged 
or repeated low-dose administration), and concomitant 
treatment in the form of radiotherapy and/or bone ma-
rrow transplantation (1).
- Clinical characteristics
Mucositis manifests as reddening (erythema), edema or 
ulceration that can be accompanied by a mild burning 
sensation. Extreme presentations in turn are characteri-
zed by large and painful ulcers that have a strong impact 
upon patient quality of life – limiting basic functions 
such as speech, eating or the swallowing saliva (2-4). 
These manifestations appear shortly after the start of 
treatment. In 18-40% of all cases they develop after ad-
ministration of the first chemotherapy cycle (6). Peak 
symptoms expression is reached after one week, fo-
llowed by gradual resolution within 2-3 weeks after the 
end of chemotherapy, provided there is no bone marrow 
suppression. Mucositis can often become overinfected, 
mainly with herpes simplex virus or Candida albicans, 
particularly in patients with prolonged neutropenia.
- Evaluation
A number of systems have been developed for measu-
rement and quantification of the oral epithelial changes, 
including general scales, multiple variable scores, and 
treatment-specific classifications (6). At present, the ge-
neral scale of the World Health Organization (WHO) is 
the most widely used system in research, combining the 
clinical appearance of the mucosa with the capacity of 
the patient to swallow food (4-6,8). In contrast, in the 
clinical setting, the most commonly used system is the 
treatment-specific classification pertaining to the Com-
mon Toxicity Criteria for Adverse Events of the United 
States National Cancer Institute (NCI), which encom-
passes the patient symptoms, the capacity to swallow 
food, and the need for treatments (1).
- Diagnosis
The diagnosis of mucositis is established from the clini-
cal characteristics. As complementary tests, studies can 
be made of lesion samples when overinfection due to 
Candida, herpes simplex virus or bacteria is suspected. 
In addition, a blood test can prove useful, since neutro-
penia, thrombopenia and dehydration are often associa-
ted. The differential diagnosis includes viral, bacterial 
and fungal oropharyngeal infections, and graft-versus-
host disease. These are disorders requiring careful con-
sideration, and which require specific and timely mana-
gement (1).
- Treatment and prevention
Correct oral hygiene and a good gingival condition du-
ring chemotherapy are associated to a lesser incidence 
and severity of mucositis (4,9). Regarding the use of 
drugs or substances for the prevention and treatment of 
mucositis, the literature offers contradictory information 
(1,3,8,9). Good results have been reported with the appli-
cation of ice before and during chemotherapy (1,4,8), and 
also with the use of iseganan hydrochloride (11). Howe-
ver, the systematic review published by Worthington et 
al. (12) found that a number of the treatments used for 
Alkylating agents Antitumor antibiotics Antimetabolites
Busulfan
Cyclophosphamide
Mechlorethamine
Procarbazine
Thiotepa
Actinomycin D
Amsacrine
Bleomycin
Mithramycin C
Mitomycin
Cytosine arabinoside
5-fluorouracil*
Hydroxyurea
Methotrexate*
6-mercaptopurine
6-thioguanine
Vinca alkaloids Anthracyclines Taxanes Others
Vinblastine*
Vincristine
Vinorelbine
Daunorubicin
Doxorubicin*
Epirubicin
Docetaxel
Paclitaxel
Etoposide*
Teniposide
Nitrogenated mustards
Table 2. Principal chemotherapeutic drugs capable of causing oral mucosal lesions. *cytostatic drugs that most often produce mucositis.
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Intensive chemotherapy, or chemotherapy involving se-
veral treatment cycles in the initial stages of hard tissue 
formation, can give rise to dental agenesis (17, 18).
•  Dental hypoplasia
Hypoplasia is characterized by small grooves, point de-
fects and fissures in the enamel in mild cases, horizontal 
rows of deep grooves in severe cases, and the absen-
ce of dental enamel in extreme cases (17). Vincristine, 
vinblastine and cyclophosphamide are the drugs most 
commonly related to the appearance of hypoplasias, dis-
colorations and opacification of the enamel, due to their 
action upon odontogenesis (18).
•  Caries
Some authors have described an increased incidence of 
caries in children subjected to chemotherapy, though the 
data are controversial, since caries may result from an 
increased use of rinses, often with a high sugar content, 
to treat hyposalivation (17,18). In adults, a number of 
studies have reported an increase in caries in patients 
subjected to chemotherapy (3,7).
- Treatment
Although the effects of cancer treatment upon the oral 
cavity are inevitable, a series of measures should be 
adopted to ensure that their impact upon patient quality 
of life is minimized. Children scheduled for chemothe-
rapy should undergo a thorough clinical and radiological 
evaluation by the dentist (4,17). Periodic checks should 
be made, every 6 months, with tartrectomy and the 
application of fluor in the dental office. The recommen-
ded tooth brushing frequency varies, though at least two 
daily brushings are advised, using fluorated toothpaste 
(17). Chlorhexidine varnish also can be applied twice a 
day as a preventive measure against caries (10,17).
3.Neurological disorders
- Etiology
Certain types of chemotherapeutic drugs, such as vin-
cristine and vinblastine, can exert direct neurotoxic 
effects (4).
- Clinical characteristics
Neurotoxicity accounts for 6% of all oral complications, 
causing discomfort and pain similar to that of pulpitis. 
The pain sensation is constant and of sudden onset, 
affecting the region of the lower molars in the absence 
of dental disease.
- Treatment
An oral and radiological exploration should be made to 
distinguish the pain from that of pulp origin. The symp-
toms usually disappear one week after chemotherapy. In 
some cases dental hypersensitivity can manifest weeks 
or months later. In these cases topical fluoride or the use 
of a desensitizing toothpaste may lessen the symptoms 
(4).
4.Salivary alterations
Saliva plays an important role in the modulation of oral 
health. In this context, deficits in the amount and quality 
the prevention of mucositis (amifostine, benzidamine, 
calcium phosphate, Chinese traditional medicine, etopo-
side in bolus form, honey, hydrolytic enzymes, pieces 
of ice, iseganan, oral care and zinc sulfate) offer only 
limited benefit, and their application moreover depends 
upon the characteristics of the patient. Other treatment 
such as palifermin (13), oral glutamine (14), granulocy-
te colony stimulating factor (G-CSF) and macrophages 
in rinses, the topical application of polyvinylpyrrolidone 
(PVP) and hyaluronic acid (15), and low-intensity la-
ser phototherapy, have been related to a decrease in the 
appearance and severity of mucositis (1). Although no 
treatment has been shown to successfully eliminate mu-
cositis, management of the pain symptoms with anesthe-
tic solutions and, according to recent studies, with mor-
phine in the form of rinses (1,4,8), can help lessen oral 
discomfort and improve patient quality of life. The use 
of artificial saliva or cholinergic agonists, and the intake 
of abundant liquids for the prevention of hyposalivation, 
help preserve the integrity of the oral mucosa (8). On the 
other hand, alcohol and smoking should be avoided. An-
tifungals in suspension or as pomades, either isolatedly 
or in combination with chlorhexidine, are used for the 
prevention and treatment of overinfection with Candida 
(16). 
2.Dental alterations
Chemotherapy can cause a range of aesthetic and functio-
nal dental problems, mostly in children treated before 5 
years of age. However, prepubertal children are also at 
risk of suffering such late effects (17).
- Physiopathology
In contrast to radiotherapy, which only affects the cells 
of the irradiated zone, chemotherapy exerts a systemic 
effect. Due to the short half-life of cytostatic drugs, the 
dental defects are generally localized, and are secondary 
to transient changes in odontoblast function, rather than 
apoptosis (4,17).
•  Crown and root morphology
The shape and size of the crown in the temporal dentition 
are not affected, since crown morphology is determined 
before birth. However, in the case of the permanent den-
tition, we can observe macrodontia with a prevalence of 
2.2-5.2%, due to the action of certain chemotherapeutic 
drugs such as vinblastine and vincristine upon the ma-
ture odontoblasts and ameloblasts (17). Chemotherapy 
also causes morphological anomalies of the dental roots. 
In this context, in children under 5 years of age we can 
observe alterations of the roots of the upper and lower 
premolars, while older children show alterations of the 
roots of the upper and lower molars, premolars and cani-
nes (17). The action of cytostatic drugs upon the micro-
tubules of the odontoblasts interrupts the formation of 
collagen fibrils and dentinal matrix secretion, giving rise 
to thin and sharp-pointed roots.
•  Agenesis-hypodontia
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On the other hand, anticancer drugs can access the oral 
cavity through diffusion from plasma in the capillaries, 
producing an unpleasant taste (8,20). The mechanisms 
underlying dysgeusia also may be related to modifica-
tions in the concentrations of sodium, potassium and 
calcium in the taste bud cell receptors (20). Other causes 
are candidiasis, viral infections and gingivitis, among 
others.
- Clinical characteristics
The patients present distorted taste sensation, describing 
a metallic or very salty taste of food. These situations 
can adversely affect patient food intake and nutritional 
condition.
- Measurement of taste sensitivity
The evaluation of patients with taste alterations requi-
res a good case history, together with specific questio-
ning (8). We can also deposit solutions with the primary 
flavors on the back of the tongue, with the purpose of 
determining whether the patient is able to correctly 
identify the flavors. Another much less frequently used 
test is electric stimulation (galvanometry), delivering an 
electric current of several microamperes onto the back 
of the tongue, to assess patient capacity to identify the 
stimulus.
- Treatment
Although dysgeusia has multiple origins, there are sim-
ple forms of treatment, such as a reduction of the dose of 
certain chemotherapeutic drugs (e.g., histone deacetyla-
se inhibitors), the treatment of oral infections, and diete-
tic counseling (8,20). In relation to this latter aspect, it is 
advisable to increase liquid intake with meals, and chew 
food slowly - thereby freeing more flavors and especia-
lly increasing saliva production. In addition, diversity 
during meals is advisable, in order to prevent taste bud 
adaptation to flavors. Other pharmacological strategies 
include zinc supplements and amifostine. However, the 
results obtained in different clinical trials have not been 
entirely satisfactory, and other treatment alternatives, 
such as vitamin D supplements, are therefore being in-
vestigated (8).
6.Infections
Cytostatic agents can affect the bone marrow, produ-
cing anemia, leukopenia and thrombopenia. As a result 
of their indirect toxicity mechanism, the oral cavity be-
comes more vulnerable to infections approximately one 
week following the administration of these drugs. Bone 
marrow function must be evaluated, since the reduction 
or absence of inflammatory phenomena causes the oral 
tissues to appear normal; infections therefore go unno-
ticed, and septicemia may result. It should be noted that 
apart from causing frequent infections, agranulocytosis 
also produces neutropenic ulcers, which are characteri-
zed by a central necrotic area, no perilesional erythema-
tous halo, and irregular margins. These ulcerations are 
generally large and painful, and may be covered by a 
of the gland secretions can exert negative effects upon 
oral mucosal health (17).
•  Salivary immunoglobulins
Chemotherapy has been shown to affect a series of sa-
livary components, such as immunoglobulins, peroxi-
dases, amylases and other proteins. Salivary immuno-
globulins protect the mucosa against traumatisms and 
microbial infections. A decrease in the salivary produc-
tion of immunoglobulins IgG and IgA could explain 
some of the oral complications of chemotherapy. In 
this sense, a decrease in IgA has been associated to the 
appearance of mucositis in patients receiving chemothe-
rapy (10). Jankovic et al., in a study of the effects of 
cytostatic drugs such as anthracycline and 5-FU in 40 
patients with different metastatic tumors, recorded lower 
IgA levels and higher IgG concentrations in unstimula-
ted saliva versus the control group, with an IgG/IgA ra-
tio of 1.53 in patients with mucositis, while the healthy 
subjects presented values of under 1.0 (10).
•  Salivary pH and chemotherapy
Some authors have reported a modification in salivary 
buffer capacity after the administration of chemothera-
py (19). However, other investigators such as Avşar et 
al. (17) or Rojas-Morales et al. (19) have observed no 
significant variations following the administration of 
cytostatic agents.
•  Xerostomia
Chemotherapy can give rise to a temporary but clinica-
lly significant decrease in salivary flow that improves 
as the bone marrow recovers (4,17). Such a decrease in 
salivary flow in turn favors the appearance of mucositis 
(1,6-9). The symptoms of xerostomia or dry mouth in-
clude dryness, burning sensation or discomfort (particu-
larly of the tongue), cracked lips, changes in the tongue 
surface, and problems in wearing removable dentures or 
drinking liquids. The condition tends to be preceded by 
a metallic taste sensation that subsequently can lead to 
dysgeusia and glossodynia secondary to the effects of 
chemotherapy upon the tongue papillae and deminerali-
zation of the nerve fibers (7,10).
In treating xerostomia it is advisable to maintain adequa-
te oral hydration by means of the regular intake of water, 
the use of saliva substitutes or cholinergic agonists such 
as pilocarpine, cevimeline or bethanechol (when pilo-
carpine proves ineffective); these measures moreover 
favor integrity of the oral mucosa (8, 17).
5.Dysgeusia
According to some estimates, 50-75% of all cancer pa-
tients who receive chemotherapy, radiotherapy or both 
can experience alterations in taste perception (8).
- Etiopathogenesis
The main cause of dysgeusia in cancer patients is the 
action of chemotherapy and radiotherapy upon oral epi-
thelial cell turnover, and the effects of such treatments 
upon nerves, taste buds and olfactory receptors (4,10). 
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fibrin membrane. They appear in both keratinized and 
non-keratinized tissues, and are associated with granu-
locyte counts of under 800 cells/μl.
•  Bacterial infections
During chemotherapy, saprophytic bacteria can beco-
me aggressive as a result of the decreased granulocy-
te presence and increased fragility of the oral mucosa. 
A number of bacteria, such as Streptococcus viridans, 
Prevotella, Fusobacterium, Actinobacillus, Actinomyce-
temcomitans and Actinomyces are associated with infec-
tions of the oral cavity in patients receiving chemothera-
py (8). Bacterial infections usually manifest locally in the 
gingival tissue, mucosa and teeth. Necrotizing gingivitis 
is the most frequent oral manifestation, accompanied in 
some cases by fever and adenopathies, particularly in 
patients with previous periodontal conditions. These in-
fections are usually treated administering a combination 
of penicillins and metronidazole, with subsequent dental 
treatment (e.g., tartrectomy).
•  Fungal infections
The majority of fungal infections of the oral cavity are 
produced by Candida albicans (4). The most prevalent 
forms of candidiasis are the pseudomembranous presen-
tation, followed by erythematous candidiasis and angle 
cheilitis (4,8). Oral infection may give rise to sepsis 
and can prove fatal if not adequately diagnosed, espe-
cially when caused by non-C. albicans species such as 
Candida tropicalis (8). The diagnosis is based on the 
clinical appearance of the lesions, the ease with which 
the necrotic surface of the lesions can be removed by 
friction, and potassium hydroxide smear preparations, 
which reveal the presence of the fungus (5). Although 
prophylactic treatment with antifungal drugs has been 
questioned, good results have been obtained with such 
treatment in immune suppressed and/or neutropenic pa-
tients (8). In the review of 17 studies published by Lalla 
et al., the prophylactic administration of fluconazole du-
ring cancer therapy was seen to reduce the prevalence of 
clinically manifest fungal infections, including systemic 
infections, to 1.9% (8). Topical and systemic antifungal 
treatment is used for oral candidiasis, combining nysta-
tin (100,000 IU/ml 3-4 times/day) and fluconazole (100 
mg/day) or ketoconazole (200 mg/day). In the case of 
resistance to these drugs, use is made of itraconazole 
(200-400 mg/day) or amphotericin B, in patients with 
very extensive and severe infections (20 mg/day) (4,8).
•  Viral infections
In most cases, viral infections produced by herpes sim-
plex virus, varicella zoster virus and Epstein-Barr vi-
rus are the result of reactivation of a latent virus, while 
infections produced by cytomegalovirus can be due to 
reactivation of a latent virus or the action of a recently 
acquired virus (4,8).
Infection produced by herpes simplex virus (HSV):  °
The incidence of oral lesions produced by recu-
rrent HSV in cancer patients with bone marrow 
suppression has decreased considerably following 
the introduction of prophylactic acyclovir (4,8). 
In patients without antiviral prophylaxis, the oral 
lesions generally manifest with chemotherapy or 
chemotherapy-radiotherapy during the most inten-
se immune suppression period. The clinical picture 
tends to be atypical, with painful ulcerations as a 
first manifestation. These lesions are crater-shaped, 
well defined with whitish margins, and are mainly 
located on the palate and gums (21). The ulcers 
tend to progress towards mucocutaneous lesions in 
a short period of time, and are slow in healing. The 
diagnosis is usually based on the clinical findings, 
though in some cases viral culture and isolation is 
recommended in order to confirm the diagnosis 
and avoid spreading of the lesions (21). Treatment 
consists of acyclovir via the oral (200-400 mg/3-5 
times a day) or intravenous route (5 mg/kg in in-
fusion during one hour every 8-12 hours), for as 
long as lesions remain (8,22). We can also use oral 
valacyclovir (500-100 mg twice a day), though the 
review published by Glenny et al. (22) did not find 
this form of therapy to be more effective than acy-
clovir. In the case of resistance to the drug, intrave-
nous foscarnet or cidofovir is an alternative option.
Infection produced by Epstein-Barr virus (EBV):  °
There have been reports of hairy leukoplakia in 
patients subjected to chemotherapy due to acute 
myeloid leukemia, acute lymphocytic leukemia 
and multiple myeloma (8). The infection is clinica-
lly characterized by elongated and elevated white 
lesions located bilaterally at the lateral margins of 
the tongue. The lesions are not removed by rasping, 
and produce no symptoms. In general, no treatment 
is indicated, since the lesions improve as the host 
immune function recovers, and they do not undergo 
malignant transformation – though high-dose oral 
valacyclovir is a safe and effective management 
option (23). Topical treatments in the form of 25% 
podophyllin resin either alone or in combination 
with topical 5% acyclovir and gentian violet have 
also been found to be safe and effective (8).
Infection produced by varicella-zoster virus (VZV):  °
In contrast to HSV, the orofacial lesions produced 
by VZV generally manifest several weeks after the 
interruption of chemotherapy (4). The patients may 
experience a series of nonspecific prodromic symp-
toms (pain or dysesthesias), followed by a vesicu-
lar eruption along a dermatome innervated in the 
maxillofacial territory by a trigeminal nerve branch 
– though in some cases multiple dermatomes can be 
affected; the lesions may exhibit a more generali-
zed distribution with more extensive skin necrosis; 
or alternatively there may be extensive hematoge-
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nous spread towards mucocutaneous structures and 
also internal organs. The pain is described as cons-
tant and burning, and the vesicles (blisters) appear 
both on the skin and on the mucosal membranes, 
without extending beyond the midline. Depending 
on the immune depression of the patient, treatment 
consists of acyclovir (800 mg 5 times a day during 
5-7 days via the oral route, or 5-10 mg/kg three ti-
mes a day during 5 days via the intravenous route), 
oral famcyclovir or valacyclovir, or intravenous 
foscarnet (40 mg/kg three times a day) in the case 
of resistance to the aforementioned drugs. Amitrip-
tyline (25-50 mg/day via oral) or anticonvulsivants 
(clonazepam, carbamazepine) can be used to treat 
the pain.
Infection produced by cytomegalovirus (CMV):  °
The lesions produced by CMV consist of multiple 
nonspecific, pseudomembranous ulcerations cove-
red by a fibrin exudate, with a granulomatous base 
and irregular margins. At present, gancyclovir is 
the treatment of choice in cases of acute CMV in-
fection (4).
7.Bleeding tendency
- Etiopathogenesis
Bleeding tendency is secondary to bone marrow su-
ppression caused by chemotherapy or the liver toxici-
ty of certain cytostatic drugs, resulting in alteration of 
the synthesis of different coagulation factors. Bleeding 
tendency in the oral cavity usually appears after trauma 
during chewing in patients with pre-existing periodontal 
disease - especially patients with prior gingivitis and a 
platelet count of under 20,000 platelets/mm3).
- Clinical characteristics
Clinically, we can observe petechiae, ecchymosis, he-
matomas or diffuse bleeding in any location of the oral 
cavity.
- Treatment
Oral rinses with 0.12% chlorhexidine avoid overinfec-
tion and can help eliminate remaining blood, though 
caution is required not to disturb the blood clots, since 
this may lead to further bleeding (4). The treatment of 
choice in cases of bleeding consists of vasoconstrictors 
such as topical norepinephrine, mucoadherent tissue pro-
tectors such as cyanoacrylate, and coagulation-favoring 
drugs such as topical thrombin or hemostatic collagen, 
which organize and stabilize the blood clots (4). In indi-
viduals subjected to chemotherapy who require invasi-
ve dental treatment, the hematological condition of the 
patient must be taken into account, with consultation of 
the supervising oncologist. In the presence of a platelet 
count of under 50,000 platelets/mm3, it is advisable to 
provide invasive dental treatment in the hospital setting, 
following transfusion assessment.
8.Osteonecrosis of the jaws due to bisphosphonates
- Terminology
Bisphosphonates (BPs) are potent inhibitors of osteoclas-
tic bone reabsorption and have been used for decades for 
the treatment of osteoporosis, malignant hypercalcemia, 
Fig. 1. Hypothesis on the mechanism underlying osteonecrosis of the jaws. Adapted from Yoneda et al. (25) // BRONJ: bisphosphonate-
related osteonecrosis of the jaw; BP: bisphosphonates. 
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solid tumor bone metastases and myeloma (4,24,25). In 
the year 2003, Marx published a first series of 36 pa-
tients with osteonecrosis of the jaws (ONJ) induced by 
the BPs zolendronate and pamidronate (26). Posteriorly, 
Ruggiero et al. published a larger series of 63 patients 
(27). In Spain, Bagán et al., in the year 2005, published 
a series of 10 patients subjected to chemotherapy with 
BPs, and who developed osteonecrosis of the jaws (28). 
With the purpose of exploring the growing problem po-
sed by this new disorder, the American Association of 
Oral and Maxillofacial Surgeons (AAOMS)(29) in 2007 
defined the diagnostic criteria of osteonecrosis of the 
jaws induced by bisphosphonates. During that same year 
in Spain, a panel of experts in Oncology, Hematology, 
Urology, Stomatology / Odontology and Maxillofacial 
Surgery published a series of recommendations for pa-
tients treated with BPs (30).
- Etiopathogenesis
The etiology of ONJ remains unclear, and although the 
underlying mechanism of action has not been fully es-
tablished, a series of factors are believed to be invol-
ved. In this context, it has been postulated that BPs 
produce osteoclast apoptosis, thereby inhibiting bone 
resorption and bone remodeling, and favoring the crea-
tion of areas of bone sequestration (4,24,25,30-33). On 
the other hand, it has been suggested that inhibition of 
this homeostatic cycle gives rise to the accumulation of 
non-vital osteocytes and microfractures in the old bone 
matrix, thereby facilitating the progression of ONJ (25). 
Some studies in turn relate ONJ to an increase in bacte-
rial microfilm, favoring bacterial adherence to the sur-
face of the tooth – particularly bacteria belonging to the 
genus Actinomyces. This could explain why such osteo-
necrosis only appears in the oral cavity (24,25). On the 
other hand, BPs may produce blood vessel obstruction 
within bone, and consequently necrosis of the osteocytes 
surrounding these vessels. By inhibiting angiogenesis, 
healing is delayed (25,31-33). In relation to this pheno-
menon, ONJ has also been observed in patients treated 
with bevacizumab (25). The inhibition of oral epithelial 
cell proliferation and migration produced by BPs may 
cause a delay in post-extraction socket healing. In turn, 
the accumulation of BPs produces alveolar bone sclero-
sis, complicating extraction and prolonging the healing 
time. Lastly, in patients of old age and/or subjected to 
treatment with chemotherapeutic drugs or corticoste-
roids, immune function may be altered, thereby increa-
sing the susceptibility to infections (25,31) (Fig. 1).
- Risk factors
The development of ONJ has been associated to a num-
ber of general risk factors, such as the type of BP admi-
nistered, the duration of treatment, the type of neoplasm, 
the existence of concomitant treatments (chemotherapy, 
head and neck radiotherapy, corticosteroids, thalidomide 
or bortezomib), and the presence of other disease condi-
tions (anemia, diabetes, obesity, hypercalcemia and coa-
gulation disorders)(25,32-36). Local risk factors in turn 
include dentoalveolar surgery, the mandibular location, 
bone protuberances (torus, mylohyoid crest) and con-
comitant oral disease (periodontal or dental infections)
(4,25,34-36). Regarding hereditary factors, ONJ has 
been related to polymorphisms of cytochrome P450-2C 
[CYP2C8] and to the COLIA-1, RANK, MMP-2, OPG, 
OPN, FPPS and FCEV genes (25,33,35,37). Other con-
tributing cofactors are alcohol, smoking, deficient oral 
hygiene, obesity and old age (25,33,32,36).
- Incidence
Osteonecrosis of the jaws produced by intravenous 
BPs is more frequent than ONJ due to oral BPs, with 
an incidence of 1-12% versus 0.01-0.04%, respectively 
(24,36,38). In the study published by Ruggiero et al. 
(34), based on case series, case-control series and cohort 
studies of patients treated with intravenous BPs up until 
the year 2006, the cumulative incidence varied between 
0.8%-12%. In later studies such as that of Bagán et al. 
(2009), the suggested incidence was 1-3% (33).
5.Clinical characteristics
Clinically, the onset of ONJ can be nonspecific. The pa-
tient may describe discomfort around a tooth, a lack of 
healing after tooth extraction, or ulceration of the oral 
mucosa (4,31). As the lesions advance, the patient may 
develop pain, exposure of necrotic bone, fistulization, 
purulent secretion, alveolar nerve paresthesia, dental 
mobility, involvement of the maxillary sinus, and man-
dibular fracture (31,32,35). In 2006, Ruggiero et al. (39) 
proposed a staging system for ONJ based on the clinical 
characteristics of the lesion. In 2009, the AAOMS pu-
blished a modification of the staging system developed 
by Ruggiero et al. (34), and posteriorly, in 2012, Bagán 
et al. (40) proposed a new classification of ONJ with the 
creation of two new subcategories in stage 2 (Table 3).
- Complementary tests
A routine panoramic X-ray study is indicated. Computed 
tomography or magnetic resonance imaging can be used 
to evaluate the magnitude and extent of necrotic bone, 
though the latter technique is less specific (30,33). Other 
complementary tests include culture and an antibiogram 
of the exposed zone. A biopsy is advised in cases of do-
ubt in differentiating between ONJ and bone metastasis 
(4,30). The evaluation of serum C-terminal telopepti-
de (CTX) is subject to controversy; some studies have 
found no statistically significant relationship between 
the CTX levels and the size or number of exposed ne-
crotic bone areas in ONJ (33,35).
- Prevention 
Since the treatment of ONJ is usually unsatisfactory and 
the condition proves difficult to control, management 
should focus on the prevention of high risk situations, 
checking the oral cavity with the purpose of carrying 
out treatment – especially when of a surgical nature 
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– between 4-6 weeks before the first infusion of BPs 
(4,25,30,35). If the patient is receiving treatment with 
BPs, it is advisable to evaluate the oral cavity every 6-12 
months (4,30,35), and any required dental treatment 
should follow a series of measures designed to lessen 
the risk of ONJ, since some therapies are considered ac-
ceptable while others are contraindicated (4,32,34,35).
- Treatment
The treatment of ONJ is controversial, and no effecti-
ve or fully consensus-based guidelines have been es-
tablished, though a number of management strategies 
have been used, such as the interruption of BPs, sur-
gical treatment, the use of hyperbaric oxygen, and the 
application of ozone, laser surgery, or low-intensity la-
ser therapy (25,30-32,34,35,38). Research is still being 
conducted on the efficacy of the treatment of ONJ with 
pentoxyphylline, α-tocopherol or teriparatide (38). Most 
authors agree that conservative management of ONJ is 
the best approach (4,28,35), since mucosal healing can 
be achieved in at least 23-53% of all patients by adop-
ting less aggressive treatments (33).
References
1. Ruiz-Esquide G, Nervi B, Vargas A, Maíz A. Treatment and pre-
vention of cancer treatment related oral mucositis. Rev Med Chil. 
2011;139:373-81.
2. Watters AL, Epstein JB, Agulnik M. Oral complications of tar-
geted cancer therapies: a narrative literature review. Oral Oncol. 
2011;47:441-8.
3. López-Galindo MP, Bagán JV, Jiménez-Soriano Y, Alpiste F, Camps 
C. Clinical evaluation of dental and periodontal status in a group of 
oncological patients before chemotherapy. Med Oral Patol Oral Cir 
Bucal. 2006;11:E17-21.
4. Chaveli López B, Gavaldá Esteve C, Sarrión Pérez MG. Dental 
treatment considerations in the chemotherapy patient. J Clin Exp Dent. 
2011;3:e31-42.
5. Caribé-Gomes F, Chimenos-Küstner E, López-López J, Finestres-
Zubeldia F, Guix-Melcior B. Dental management of the complications 
of radio and chemotherapy in oral cancer. Med Oral. 2003;83:178-87.
6. López-Castaño F, Oñate-Sánchez RE, Roldán-Chicano R, Cabreri-
zo-Merino MC. Measurement of secondary mucositis to oncohemato-
logic treatment by means of different scale. Review. Med Oral Patol 
Oral Cir Bucal. 2005;10:412-21.
7. Chan CW, Chang AM, Molassiotis A, Lee IY, Lee GC. Oral compli-
cations in Chinese cancer patients undergoing chemotherapy. Support 
Care Cancer. 2003;1:48-55.
8. Mosel DD, Bauer RL, Lynch DP, Hwang ST. Oral complications in 
the treatment of cancer patients. Oral Dis. 2011;17:550-9.
9. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-
Durlacher JE, et al. Updated clinical practice guidelines for the preven-
tion and treatment of mucositis. Cancer. 2007;109:820-31.
CLASSIFICATION OF RUGGIERO et al. (2006) 
AND MODIFICATION BY AAOMS (2009)
CLASSIFICATION OF BAGAN et al. (2012)
BRONJ STAGE DESCRIPTION BRONJ STAGE DESCRIPTION TREATMENT
STAGE 0 No clinical evidence of necrotic 
bone. Nonspecific clinical findings 
and symptoms.
STAGE 0 No clinical evidence of necrotic bone. Non-
specific clinical findings and symptoms.
Symptomatic treat-
ment, including anal-
gesics and antibiotics.
STAGE 1 Bone exposure. Necrotic bone. As-
ymptomatic.
No clinical evidence of infection.
STAGE 1 Bone exposure with necrotic bone or a small 
ulceration of the oral mucosa without ne-
crotic bone exposure. Both forms would be 
asymptomatic.
Daily rinse with 0.12% 
chlorhexidine + fol-
low-up.
STAGE 2 Bone exposure. Necrotic bone. Pain 
and infection of the soft tissues/
bone.
STAGE 2A Bone exposure with necrotic bone or a small 
ulceration of the oral mucosa without necrot-
ic bone exposure, but with symptoms: pain 
and infection of the soft tissues/bone. Can 
be controlled by conservative measures and 
does not progress.
Daily rinse with 0.12% 
chlorhexidine + antibi-
otics + analgesics + 
follow-up.
STAGE 2B Bone exposure with necrotic bone or a small 
ulceration of the oral mucosa without necrot-
ic bone exposure, but with symptoms: pain 
and infection of the soft tissues/bone. Not 
controlled by conservative treatment, and 
necrosis or the derived infectious signs are 
seen to progress.
Daily rinse with 0.12% 
chlorhexidine + antibi-
otics + analgesics + 
surgery with elimina-
tion of the bone ne-
crosis.
STAGE 3
Bone exposure. Necrotic bone. 
Pain, infection and one or more of 
the following: pathological fracture, 
extraoral fistula or osteolysis exten-
ding to the lower mandibular mar-
gin or floor of the maxillary sinus.
STAGE 3 Bone exposure. Necrotic bone. Pain, infec-
tion and one or more of the following: patho-
logical fracture, extraoral fistula or osteolysis 
extending to the lower mandibular margin or 
floor of the maxillary sinus.
Daily rinse with 0.12% 
chlorhexidine + antibi-
otics + analgesics + 
extensive surgery with 
bone resection.
Table 3. Clinical classification of ONJ developed by Ruggiero (2006), posteriorly modified by the American Association of Oral and Maxillofacial 
Surgeons (AAOMS, 2009) and the classification of Bagán et al. (2012) (39,34,40).// BRONJ: bisphosphonate-related osteonecrosis of the jaw.
e90
J Clin Exp Dent. 2014;6(1):e81-90. Oral toxicity due to chemotherapy
10. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary 
function in modulating chemotherapy-induced oropharyngeal muco-
sitis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod. 2002;94:39-44.
11. Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis 
ST, et al. A phase III, randomized, double-blind, placebo-controlled, 
multinational trial of iseganan for the prevention of oral mucositis in 
patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). 
Leuk Lymphoma. 2003;44:1165-72.
12. Worthington HV, Clarkson JE, Eden OB. Interventions for pre-
venting oral mucositis for patients with cancer receiving treatment. 
Cochrane Database Syst Rev. 2007;4:CD000978.
13. Schmidt E, Thoennissen NH, Rudat A, Bieker R, Schliemann C, 
Mesters RM, et al. Use of palifermin for the prevention of high-dose 
methotrexate-induced oral mucositis. Ann Oncol. 2008;19:1644-9.
14. Peterson DE, Jones JB, Petit RG 2nd. Randomized, placebo-con-
trolled trial of Saforis for prevention and treatment of oral mucositis 
in breast cancer patients receiving anthracycline-based chemotherapy. 
Cancer. 2007;109:322-31.
15. Innocenti M, Moscatelli G, Lopez S. Efficacy of gelclair in reducing 
pain in palliative care patients with oral lesions: preliminary findings 
from an open pilot study. J Pain Symptom Manage. 2002;24:456-7.
16. Chen YK, Hou HA, Chow JM, Chen YC, Hsueh PR, Tien HF. The 
impact of oral herpes simplex virus infection and candidiasis on che-
motherapy-induced oral mucositis among patients with hematological 
malignancies. Eur J Clin Microbiol Infect Dis. 2011;30:753-9.
17. Avşar A, Elli M, Darka O, Pinarli G. Long-term effects of chemo-
therapy on caries formation, dental development, and salivary factors 
in childhood cancer survivors. Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod. 2007;104:781-9.
18. Oğuz A, Cetiner S, Karadeniz C, Alpaslan G, Alpaslan C, Pinarli 
G. Long-term effects of chemotherapy on orodental structures in chil-
dren with non-Hodgkin’s lymphoma. Eur J Oral Sci. 2004;112:8-11.
19. Rojas-Morales T, Lugo Z, Santana Y, Navas R, Zambrano O, Viera 
N, et al. Capacity buffer of the saliva in children and adolescents with 
cancer: Variations induced by the administration of Metotrexate or Cy-
clophosphamide. Med Oral Patol Oral Cir Bucal. 2005;10:E103-8.
20. Cowart BJ. Taste dysfunction: a practical guide for oral medicine. 
Oral Dis. 2011;17:2-6.
21. Sepúlveda E, Brethauer U, Rojas J, Fernández E, Le Fort P. Oral 
ulcers in children under chemotherapy: clinical characteristics and 
their relation with Herpes Simplex Virus type 1 and Candida albicans. 
Med Oral Patol Oral Cir Bucal. 2005;10:E1-8.
22. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. In-
terventions for the prevention and treatment of herpes simplex virus 
in patients being treated for cancer. Cochrane Database Syst Rev. 
2009;1:CD006706.
23. Walling DM, Flaitz CM, Nichols CM. Epstein-Barr virus replica-
tion in oral hairy leukoplakia: response, persistence, and resistance to 
treatment with valacyclovir. J Infect Dis. 2003;188:883-90.
24. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteo-
necrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin 
Oncol. 2010;136:1117-24.
25. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, 
et al. Bisphosphonate-related osteonecrosis of the jaw: position paper 
from the Allied Task Force Committee of Japanese Society for Bone 
and Mineral Research, Japan Osteoporosis Society, Japanese Society 
of Periodontology, Japanese Society for Oral and Maxillofacial Radio-
logy, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone 
Miner Metab. 2010;28:365-83.
26. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced 
avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac 
Surg. 2003;61:1115-7.
27. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecro-
sis of the jaws associated with the use of bisphosphonates: a review of 
63 cases. J Oral Maxillofac Surg. 2004;62:527-34.
28. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis 
JM, et al. Avascular jaw osteonecrosis in association with cancer che-
motherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120-3.
29. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis 
of the Jaws, American Association of Oral and Maxillofacial Sur-
geons. American Association of Oral and Maxillofacial Surgeons posi-
tion paper on bisphosphonate-related osteonecrosis of the jaws. J Oral 
Maxillofac Surg. 2007;65:369-76.
30. Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez 
Veiga F, et al. Recommendations for the prevention, diagnosis, and 
treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated 
with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:E336-
40.
31. Gómez Font R, Martínez García ML, Olmos Martínez JM. Osteo-
chemonecrosis of the jaws due to bisphosphonate treatments. Update. 
Med Oral Patol Oral Cir Bucal. 2008;13:E318-24.
32. Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour 
S. Bisphosphonates-related osteonecrosis of the jaws: a concise review 
of the literature and a report of a single-centre experience with 151 
patients. J Oral Pathol Med. 2012;41:214-21.
33. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws 
in patients treated with intravenous bisphosphonates (BRONJ): A con-
cise update. Oral Oncol. 2009;45:551-4.
34. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, 
Mehrotra B, et al. American Association of Oral and Maxillofacial 
Surgeons position paper on bisphosphonate-related osteonecrosis of 
the jaw - 2009 update. Aust Endod J. 2009;35:119-30.
35. Fedele S, Kumar N, Davies R, Fiske J, Greening S, Porter S. Den-
tal management of patients at risk of osteochemonecrosis of the jaws: 
a critical review. Oral Dis. 2009;15:527-37.
36. Chaveli López B, Sarrión Pérez MG, Jiménez Soriano Y. Den-
tal considerations in pregnancy and menopause. J Clin Exp Dent. 
2011;3:e135-44.
37. Arduino PG, Menegatti E, Scoletta M, Battaglio C, Mozzati M, 
Chiecchio A, et al. Vascular endothelial growth factor genetic po-
lymorphisms and haplotypes in female patients with bisphosphonate-
related osteonecrosis of the jaws. J Oral Pathol Med. 2011;40:510-5.
38. Vescovi P. Bisphosphonates and osteonecrosis: an open matter. 
Clin Cases Miner Bone Metab. 2012;9:142-4.
39. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn 
JM, et al. Practical guidelines for the prevention, diagnosis, and 
treatment of osteonecrosis of the jaw in patients with cancer. J Oncol 
Pract. 2006;2:7-14.
40. Bagan JV, Hens-Aumente E, Leopoldo-Rodado M, Poveda-Roda 
R, Bagan L. Bisphosphonate-related osteonecrosis of the jaws: stu-
dy of the staging system in a series of clinical cases. Oral Oncol. 
2012;48:753-7.
Conflict of interest
The authors declare that they have no conflict of interest.
